Search - tctmd.com

Displaying 21 - 30 of 30

Sort: Relevancy | Date

Presentation TCT 2017

What Is the Optimal DAPT Duration With ABSORB? Results From a Comprehensive Meta-Analysis

Presenter: Azeem Latib, Gregg W. Stone

October 31, 2017

Presentation TCT 2016

To Pretreat or Not to Pretreat? The DUBIUS Trial

Presenter: Roxana Mehran, Ferdinando Varbella, Giuseppe Tarantini

November 01, 2016

Presentation TCT 2016

Debate: What Is the Optimal Study Design for Maximizing Trial Efficiency, Success, and Interpretability? Adaptive Design in A Bayesian Framework!

Presenter: Roxana Mehran, Pascal Vranckx, Scott Berry

October 30, 2016

Presentation TCT 2016

Debate: What Is the Optimal Study Design for Maximizing Trial Efficiency, Success, and Interpretability? Adaptive Design in a Frequentist Framework!

Presenter: Roxana Mehran, Pascal Vranckx, Stuart J. Pocock

October 30, 2016

Presentation TCT 2013

The Common Dilemma of Managing Operator Learning Curve Issues and Evolving Clinical Trial Considerations (eg, Control Populations, Clinical Indications, and Optimal Endpoints)

Presenter: Ted Feldman

October 30, 2013

Presentation TCT 2013

Optimal Management of Multivessel Disease in Patients Undergoing Primary PCI: Design and Rationale of the Multinational COMPLETE Trial

Presenter: Shamir Mehta

October 30, 2013

Presentation TCT 2012

TCT-43. Final Five-year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients with Three-vessel Disease

Presenter: A. Pieter Kappetein

October 23, 2012

Presentation

Optimal Anticoagulant/Antiplatelet Therapy in Challenging Subsets: A Post-ESC Late Breaking Trial Roundup

Presenter: 62744|Gregg Stone

September 18, 2012

Presentation

Randomized Trial of Optimal Treatment Strategies for In-Stent Restenosis After DES Implantation

Presenter: H. Song

March 12, 2012

Presentation TCT 2012

Four-year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients with Three-vessel Disease and/or Left Main Disease

Presenter: David R. Holmes, Brad Vazales, Louis A. Cannon, Elisabeth Stahle, Marie-Claude Morice, Michael J. Mack, Ted E. Feldman, A. Pieter Kappetein, Antonio Colombo, Keith D. Dawkins, Friedrich W. Mohr, Patrick W. Serruys

January 03, 2012

Advertisement

What Is the Optimal DAPT Duration With ABSORB? Results From a Comprehensive Meta-Analysis

To Pretreat or Not to Pretreat? The DUBIUS Trial

Debate: What Is the Optimal Study Design for Maximizing Trial Efficiency, Success, and Interpretability? Adaptive Design in A Bayesian Framework!

Debate: What Is the Optimal Study Design for Maximizing Trial Efficiency, Success, and Interpretability? Adaptive Design in a Frequentist Framework!

The Common Dilemma of Managing Operator Learning Curve Issues and Evolving Clinical Trial Considerations (eg, Control Populations, Clinical Indications, and Optimal Endpoints)

Optimal Management of Multivessel Disease in Patients Undergoing Primary PCI: Design and Rationale of the Multinational COMPLETE Trial

TCT-43. Final Five-year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients with Three-vessel Disease

Optimal Anticoagulant/Antiplatelet Therapy in Challenging Subsets: A Post-ESC Late Breaking Trial Roundup

Randomized Trial of Optimal Treatment Strategies for In-Stent Restenosis After DES Implantation

Four-year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients with Three-vessel Disease and/or Left Main Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content